The Ibr‐7 derivative of ibrutinib exhibits enhanced cytotoxicity against non‐small cell lung cancer cells via targeting of mTORC1/S6 signaling
Ibrutinib is a small molecule drug that targets Bruton's tyrosine kinase in B‐cell malignancies and is highly efficient at killing mantle cell lymphoma and chronic lymphocytic leukemia. However, the anti‐cancer activity of ibrutinib against solid tumors, such as non‐small cell lung cancer (NSCL...
Main Authors: | Bo Zhang, Linling Wang, Qi Zhang, Youyou Yan, Hong Jiang, Runlei Hu, Xinglu Zhou, Xingguo Liu, Jianguo Feng, Nengming Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-04-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.12454 |
Similar Items
-
The Ibr-7 derivative of ibrutinib radiosensitizes pancreatic cancer cells by downregulating p-EGFR
by: Biqin Tan, et al.
Published: (2020-09-01) -
mTORC1 and mTORC2 are differentially engaged in the development of laser-induced CNV
by: Jin Young Yang, et al.
Published: (2019-06-01) -
A Positive Feedback Loop between Sestrin2 and mTORC2 Is Required for the Survival of Glutamine-Depleted Lung Cancer Cells
by: Jun-Kyu Byun, et al.
Published: (2017-07-01) -
mTORC1 is necessary but mTORC2 and GSK3β are inhibitory for AKT3-induced axon regeneration in the central nervous system
by: Linqing Miao, et al.
Published: (2016-03-01) -
Pathological Consequences of Hepatic mTORC1 Dysregulation
by: Chun-Seok Cho, et al.
Published: (2020-08-01)